Fig. 5.
SIRT1 does not influence physiological response to long-term PPARα agonist treatment. Sirt1F/F and Sirt1ΔLiv mice were treated with WY for 3 mo. A: liver/body mass ratio and serum triglyceride, cholesterol, and NEFA concentrations. B: hepatic concentrations of total triglycerides, cholesterol, and NEFAs. Significant differences between control and WY treatment are indicated (*P < 0.05). Significant differences between Sirt1F/F and Sirt1ΔLiv mice are indicated (†P < 0.05).